Aravan Labs

Aravan Labs is a biotechnology company based in South San Francisco dedicated to discovering and developing next-generation small molecule therapeutics. The company focuses on targeting "undruggable" protein-protein interactions (PPIs) that are central to cancer progression and therapeutic resistance. By leveraging its proprietary discovery platform, Aravan Labs aims to create highly selective inhibitors for validated but historically challenging oncogenic targets. Their current pipeline is in the pre-clinical stage, focusing on high-impact targets within oncology and solid tumors. The company utilizes advanced structural biology and computational chemistry to address complex molecular interfaces.